|
Market Closed -
Nasdaq
16:00:00 2026-08-14 EDT
|
5-day change | 1st Jan Change | ||
| 8.210 USD | -0.85% |
|
+40.58% | -42.14% |
| 08-12 | RTW Biotech's Avere to go public in US in reverse merger with NextCure | AN |
| 08-12 | RTW Biotech to Inject $6 Million in Avere Therapeutics Ahead of Reverse Merger | MT |
| Market Cap | 37.58M 32.46M 30.5M 27.74M 52.15M 3.59B 53.01M 357M 140M 1.8B 141M 138M 5.98B | P/E 2026 * |
-1.16x | P/E 2027 * | -1.25x |
|---|---|---|---|---|---|
| Enterprise Value | 37.58M 32.46M 30.5M 27.74M 52.15M 3.59B 53.01M 357M 140M 1.8B 141M 138M 5.98B | EV / Sales 2026 * |
-
| EV / Sales 2027 * | - |
| Free-Float |
88.32% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: NextCure, Inc.
| 1 day | -0.85% | ||
| 1 week | +40.58% | ||
| Current month | +98.07% | ||
| 1 month | +24.77% | ||
| 3 months | -19.90% | ||
| 6 months | -37.33% | ||
| Current year | -42.14% |
| 1 week | 5.91 |  | 8.72 |
| 1 month | 3.95 | | 8.72 |
| Current year | 1.55 | | 14.65 |
| 1 year | 1.55 | | 15.74 |
| 3 years | 1.55 | | 30.84 |
| 5 years | 1.55 | | 110.16 |
| 10 years | 1.55 | | 1,308 |
| Manager | Title | Age | Since |
|---|---|---|---|
Michael Richman
CEO | Chief Executive Officer | 65 | 2015-11-30 |
Steven Cobourn
DFI | Director of Finance/CFO | 63 | 2017-12-31 |
Udayan Guha
CTO | Chief Tech/Sci/R&D Officer | 54 | 2023-02-28 |
| Director | Title | Age | Since |
|---|---|---|---|
Michael Richman
BRD | Director/Board Member | 65 | 2015-11-30 |
Elaine Jones
BRD | Director/Board Member | 71 | 2015-11-30 |
David Kabakoff
CHM | Chairman | 78 | 2015-11-30 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 8/10/26 | Sell | Company | -30,000 | 1.1210% | ||
| 7/31/26 | Adar1 Capital Management LLC
| Buy | Company | 36,303 | 1.3566% | |
| 7/29/26 | Adar1 Capital Management LLC
| Buy | Company | 3,410 | 0.1274% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.85% | +40.58% | +59.49% | -60.90% | 37.58M | |
| -1.90% | +2.85% | +61.37% | +102.88% | 70.07B | |
| -3.21% | -4.32% | +31.19% | +59.75% | 52.87B | |
| -2.05% | -5.61% | -3.14% | +454.89% | 27.02B | |
| -1.27% | -1.57% | +46.46% | +6.09% | 23.61B | |
| +1.05% | -0.62% | -17.40% | -13.36% | 23.38B | |
| +3.81% | +20.97% | +263.48% | +552.47% | 19.43B | |
| +0.10% | +1.40% | +38.98% | -20.04% | 18.75B | |
| -0.95% | -3.52% | +20.04% | +613.01% | 15.85B | |
| +1.24% | -5.23% | +33.19% | +138.21% | 12.7B | |
| Average | -0.40% | +6.56% | +53.37% | +183.30% | 26.37B | |
| Weighted average by Cap. | -1.09% | +0.56% | +49.85% | +168.06% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | - | - |
| Net income | -33.8M -29.19M -27.43M -24.95M -46.9M -3.23B -47.68M -321M -126M -1.62B -127M -124M -5.38B | -49.62M -42.86M -40.28M -36.63M -68.87M -4.75B -70M -472M -185M -2.38B -186M -182M -7.9B |
| Net Debt | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-08-14 | US$8.210 | -0.85% | 262,004 |
| 26-08-13 | US$8.280 | +1.35% | 286,103 |
| 26-08-12 | US$8.170 | +21.40% | 493,351 |
| 26-08-11 | US$6.730 | -1.61% | 181,443 |
| 26-08-10 | US$6.840 | +17.12% | 1,394,534 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- NXTC Stock
Select your edition
All financial news and data tailored to specific country editions
